Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods
Portfolio Pulse from Nina Zdinjak
Enveric Biosciences (NASDAQ:ENVB), a psychedelics biotech firm, has signed a $61M non-binding term sheet for exclusive licensing of two patented methods using cannabinoids with chemotherapy for cancer treatment. The licensee, undisclosed, will handle all future development, with Enveric receiving up to $61M plus 2.5% to 10% royalties on sales. This deal highlights Enveric's discovery capabilities and its potential in advancing cancer treatments.
May 08, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enveric Biosciences has entered a significant licensing agreement potentially worth $61M plus royalties for its patented cancer treatment methods, indicating a strong future revenue stream and innovation in cancer treatment.
The licensing deal not only brings in a potential $61M plus royalties for Enveric but also validates its research and development capabilities in the biotech and cancer treatment space. This agreement could significantly impact Enveric's financials and its position in the market as a leader in innovative cancer treatments, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100